p53 overexpression in the multistep process of esophageal carcinogenesis
- PMID: 7503363
- DOI: 10.1097/00000478-199512000-00008
p53 overexpression in the multistep process of esophageal carcinogenesis
Abstract
The timing of p53 mutation in the multistep process of esophageal carcinogenesis is still under debate. We tested p53 expression in 16 samples of low-grade and 29 samples of high-grade esophageal dysplasia (ED) coexisting with esophageal squamous cancer (ESC) in 31 patients who underwent total esophagectomy. In normal mucosa, a positive immunoreaction was detected in 10 of 31 cases, always restricted to the lower half of the epithelial thickness. We detected p53-positive nuclei in 11 of 16, 23 of 29, and 23 of 31 samples of low-grade ED, high-grade ED, and ESC, respectively. Cases exhibiting positive staining in dysplastic samples also demonstrated positive immunoreaction in the carcinomatous tissue. Immunoreactivity in cancer cells was never found in the absence of positive dysplastic nuclei. A significantly higher score of immunoreactive nuclei was detected in high-grade versus low-grade and in low-grade compared with normal mucosa. These data suggest that p53 mutation may represent an early event in esophageal oncogenesis.
Similar articles
-
Ki-67 and ProExC are useful immunohistochemical markers in esophageal squamous intraepithelial neoplasia.Hum Pathol. 2011 Oct;42(10):1430-7. doi: 10.1016/j.humpath.2010.12.009. Epub 2011 Mar 21. Hum Pathol. 2011. PMID: 21420715
-
Alterations of p53, cyclin D1 and pRB expression in the carcinogenesis of esophageal squamous cell carcinoma.Oncol Rep. 2005 Dec;14(6):1453-9. doi: 10.3892/or.14.6.1453. Oncol Rep. 2005. PMID: 16273238
-
Role of p53 gene mutations in human esophageal carcinogenesis: results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions.Carcinogenesis. 1999 Apr;20(4):591-7. doi: 10.1093/carcin/20.4.591. Carcinogenesis. 1999. PMID: 10223186
-
Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.Cancer. 1999 Sep 1;86(5):756-63. doi: 10.1002/(sici)1097-0142(19990901)86:5<756::aid-cncr9>3.0.co;2-x. Cancer. 1999. PMID: 10463972
-
Squamous dysplasia and other precursor lesions related to esophageal squamous cell carcinoma.Gastroenterol Clin North Am. 2007 Dec;36(4):797-811, v-vi. doi: 10.1016/j.gtc.2007.08.005. Gastroenterol Clin North Am. 2007. PMID: 17996791 Review.
Cited by
-
Heterogeneity of p53 mutational status in esophageal squamous cell carcinoma.Jpn J Cancer Res. 1998 Apr;89(4):405-10. doi: 10.1111/j.1349-7006.1998.tb00578.x. Jpn J Cancer Res. 1998. PMID: 9617346 Free PMC article.
-
Insulin-like growth factor-binding protein-3 promotes transforming growth factor-{beta}1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells.Carcinogenesis. 2010 Aug;31(8):1344-53. doi: 10.1093/carcin/bgq108. Epub 2010 May 31. Carcinogenesis. 2010. PMID: 20513670 Free PMC article.
-
Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis.Int J Clin Oncol. 2010 Apr;15(2):135-44. doi: 10.1007/s10147-010-0057-6. Epub 2010 Mar 12. Int J Clin Oncol. 2010. PMID: 20224883 Review.
-
Study of p53 gene alteration as a biomarker to evaluate the malignant risk of Lugol-unstained lesion with non-dysplasia in the oesophagus.Br J Cancer. 2007 Feb 12;96(3):492-8. doi: 10.1038/sj.bjc.6603582. Br J Cancer. 2007. PMID: 17285122 Free PMC article.
-
A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion.Cancer Biol Ther. 2013 Sep;14(9):853-9. doi: 10.4161/cbt.25406. Epub 2013 Jun 18. Cancer Biol Ther. 2013. PMID: 23792586 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous